This is a pilot, open-label study to assess the safety and feasibility of using investigational drug(s) as rescue therapies for CAR T cell related CRS and HLH-like syndrome (CRHLS).
Philadelphia, Pennsylvania 19104, United States
Signed, written informed consent
Male or female patients age ≥ 18 years
Have been co-enrolled in a University of Pennsylvania-Sponsored, CCI-Initiated CAR T cell clinical trial.
Subjects of reproductive potential must agree to use acceptable birth control methods, as described in protocol
Pregnant or nursing (lactating) women.
Known hypersensitivity to the active substance or one of the excipients of the investigational product(s).
Study Contact Info
Contact Listings Owner Form
Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome 0 reviewsWrite Your Review
There are no reviews yet.
Write Your Review
Cohort 1: Will allow for the use of Tadekinig alfa, an interleukin-18 binding protein that binds and neutralizes IL-18. IL-18 is a key mediator in systemic inflammatory conditions such as MAS/HLH, which may contribute to the severity of CAR T cell-related cytokine release syndrome (CRS) and HLH-like syndrome (CRHLS) and impact response to standard therapy. In addition, subjects experiencing other IL-18 driven toxicity post CAR T cell therapy which is non-responsive to conventional treatment may also receive rescue therapy with Tadekinig alfa as per clinical discretion.